EUVIMEDOpdag EUVIMED
CrossrefInfokort

TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

Simone Mosna, Dorothee Dormann

BioEssays · 2026-01 · 48 (1)

DOI: 10.1002/bies.70084 ↗
AbstractBibliografiske oplysninger

Abstract

ABSTRACT TDP‐43 is a ubiquitously expressed RNA‐binding protein that aggregates in the brains of patients suffering from neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease. Aggregated TDP‐43 in these diseases is hyperphosphorylated in its C‐terminal intrinsically disordered region, while physiological TDP‐43 is normally unphosphorylated. Whether TDP‐43 phosphorylation is a pathological driver, or rather a protective antagonist of TDP‐43 aggregation and consequently neurodegeneration, is still debated and a matter of ongoing research. Here, we review current knowledge about TDP‐43 phosphorylation in disease and the kinases and phosphatases that regulate this post‐translational modification. We discuss how TDP‐43 phosphorylation is thought to shape TDP‐43's phase separation, aggregation and toxicity in neurodegenerative diseases. We highlight recent research that provides evidence that hyperphosphorylation antagonizes TDP‐43 phase separation and aggregation, and speculate about a potential role of condensates in TDP‐43 phosphorylation.

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.

Se priser →